Mario Perro

IGI Technologies (United States) — United States

Medicine · Health Sciences

25h-index5.5kcitations118works4.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(43), CAR-T cell therapy research(42), Cancer Immunotherapy and Biomarkers(27), Radiopharmaceutical Chemistry and Applications(22), Immunotherapy and Immune Responses(20)

Publications118 total

554 Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a BCMAxCD38xCD3 trispecific antibody, in TRIgnite-1, the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma (RRMM)
Regular and Young Investigator Award Abstracts·2025Open Access
Abstract CT147: Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a novel BCMAxCD38xCD3 trispecific antibody from the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma patients
Cancer Research·2025
Abstract 3413: Discovery of GRC 65327, a best-in-class, selective and potent Cbl-b inhibitor for the treatment of advanced solid cancers
Cancer Research·2025
Abstract 3694: Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed refractory multiple myeloma (RRMM) patients
Cancer Research·2025· 1 cited
Abstract A102: Assessment of CIT-drugs MoA with in vivo and 3D in vitro imaging
Cancer Immunology Research·2025
ISB 2001: Accelerating Patient Benefits through Quantitative Systems Pharmacology (QSP) Guided First-in-Human (FIH) Starting Dose Selection
Blood·2024Open Access
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Nature Cancer·2024· 29 citedOpen Access
Abstract 7534: Tobemstomig, a novel bispecific checkpoint inhibitory antibody to preferentially block PD-1 and LAG-3 on CD8 TILs over Tregs
Cancer Research·2024· 2 cited
Abstract 1238: ISB 2001, a BCMA and CD38 dual targeting T cell engager, demonstrates superior cytotoxicity relative to teclistamab in the samples of patient relapsing from CD38 and BCMA targeted immunotherapies
Cancer Research·2024
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
Nature Communications·2024· 16 citedOpen Access
A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma
Blood·2023· 4 cited
Integrated Preclinical Data Analysis of ISB 2001 Enables Optimal Starting Dose Selection for a First-in-Class Trispecific T Cell Engager Phase1 Study in Multiple Myeloma
Blood·2023· 1 citedOpen Access
Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
Blood·2023· 9 cited
Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed/refractory multiple myeloma
Blood·2023· 19 citedOpen Access
Abstract 2970: Overcoming mechanisms of escape from treatments for multiple myeloma with ISB 2001, a potential first-in-class trispecific BCMA and CD38 targeted T cell engager
Cancer Research·2023· 1 cited
Data from CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
2023Open Access
Video 2 from CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
2023Open Access
Data from CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
2023Open Access
Supplemental Figure 2 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
Table S2 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Christian Klein(15), Sara Colombetti(14), Pablo Umaña(14), Marina Bacac(12), Johannes Sam(9), Valeria Nicolini(9), Ulrich H. von Andrian(7), Dario Speziale(7), Vinu Menon(7), Cyril Konto(7), Bodo Grimbacher(6), Caleb Stoltzfus(6), Michael Y. Gerner(6), Leo Kunz(6), Elena Menietti(6), Carole Estoppey(6), Thierry Monney(6), Maria Pihlgren(6), Stefano Sammicheli(5), Brandy Olin(5)